Back to results
US 2016/0256487 A1Published application
Polyclonal gamma delta t cells for immunotherapy
AssigneeBoard of Regents, The University of Texas System
InventorsLaurence J.N. COOPER, Drew C. DENIGER
Life of this patent
Estimating the term…
Abstract
Provided herein is a method of expanding clinically-relevant quantities of polyclonal γδ T cells that have anti-tumor, anti-viral, and anti-bacterial reactivity. Polyclonal γδ T cells can target a variety of tumors, including solid tumors as well as other conditions, such as viral and bacterial infections.
Claims56
A cell composition comprising at least about 109 purified γδ T cells, wherein the γδ T cells:
- (a) are of the Vδ1, Vδ2, and Vδ1negVδ2neg TCR subsets;
- (b) have essentially identical genetic material;
- and
- (c) do not contain a chimeric antigen receptor.
1 more element
Dependencies are inferred from the claim text.